MK-677 Peptide Dosing Guide: Optimal Protocols

Overview

MK-677 (ibutamoren) is an oral growth hormone secretagogue discussed in research contexts. Unlike injectable peptides, MK-677 is taken by mouth, mimics the hunger hormone ghrelin, and stimulates growth hormone (GH) release from the pituitary gland. This guide explains the dosing patterns commonly discussed in research and peptide communities, presented as a text-based dosage chart for discussion with a licensed healthcare provider. You can use our MK-677 dosage calculator → to check protocol math and dose conversions — for educational purposes only.

What is MK-677?

MK-677 (ibutamoren mesylate) is a non-peptide growth hormone secretagogue — an orally active compound that binds ghrelin receptors and stimulates natural GH release. Research interest centers on its effects on GH and IGF-1 levels, sleep, appetite, and body composition.

Key characteristics:

Mechanism: Oral ghrelin receptor agonist that amplifies the natural GH pulse rather than replacing GH
Route: Oral (capsule or solution) — not an injectable peptide
Legal status: Not FDA-approved — research only
Half-life: ~24 hours, allowing once-daily dosing
Category: Growth hormone secretagogue

To check dose conversions and protocol math, see our MK-677 dosage calculator →

MK-677 dosage chart

There is no established FDA-approved dose for MK-677. The chart below summarizes dosing patterns drawn from published research protocols and peptide community discussions. It is intended for educational reference only — not as a personal dosing plan or medical recommendation.

Protocol Phase	Dose Range	Route	Frequency	Duration	Use Case
Standard research	10-25 mg per day	Oral	Once daily	4-8 weeks	Most common research protocol
Lower-dose exploratory	5-10 mg per day	Oral	Once daily	4-6 weeks	Conservative start; assess tolerance
Moderate	12.5 mg per day	Oral	Once daily	8-12 weeks	Frequently discussed mid-range dose
Higher-dose	25 mg per day	Oral	Once-daily dosing	4-8 weeks	Upper discussed range in literature
Cycle break	No dose	—	—	2-4 weeks	Recovery period

Reference points from clinical research: In published studies, MK-677 has most commonly been administered orally at 10 mg or 25 mg once daily (for example, a 25 mg daily oral dose was used in studies of GH response in elderly subjects and in sleep studies). The 25 mg dose is the upper discussed range — it is not a validated therapeutic dose, and higher is not better.

For dose conversions and protocol math, see our MK-677 dosage calculator →

How MK-677 works

MK-677 is an orally active ghrelin receptor agonist. By mimicking ghrelin signaling, it increases the amplitude of natural GH pulses, which in turn raises IGF-1 levels over days to weeks. Because its half-life is roughly 24 hours, once-daily oral dosing maintains elevated GH/IGF-1 exposure in research settings.

For quick protocol math based on these ranges, use our MK-677 dosage calculator →

Administration routes

MK-677 is administered orally in research settings — typically as a capsule or an oral solution/suspension. It is not a lyophilized injectable peptide: there is no bacteriostatic-water reconstitution step. Users handling bulk powder or solutions for research should follow lab safety practices. Oral bioavailability means dose timing (often evening, in sleep research) is the main variable discussed.

For unit conversions for research solutions, see our MK-677 dosage calculator →

Cycle structure and timing

Research protocols for MK-677 typically run 4-12 weeks of continuous daily oral dosing, sometimes followed by a break period. IGF-1 levels take several weeks to reach a new steady state, which is why durations in research are typically one to three months. The specific duration and any break should be discussed with a qualified professional.

Safety considerations

MK-677 is not FDA-approved for human use. Commonly reported effects in research include increased appetite, transient water retention, and elevations in fasting glucose/insulin resistance markers. Some studies in Alzheimer's research reported a higher rate of fasting glucose issues at 25 mg daily. All dosing information in this guide is presented for educational and research purposes only. Consult a licensed healthcare provider before considering any protocol.

Frequently asked questions

See the FAQ section below for common questions about MK-677 dosing, administration, and research status.

Related Peptides

Frequently Asked Questions

What is the typical dose of MK-677?

Research protocols most commonly discuss 10-25 mg taken orally once daily, with 25 mg daily being the most-studied dose in clinical literature. These ranges come from published studies, not FDA-approved guidelines. No established therapeutic dose exists for MK-677.

How is MK-677 administered?

MK-677 is taken orally (capsule or solution), once daily. It is an orally active ghrelin receptor agonist, not an injectable peptide, so it does not require reconstitution. Dose timing is often discussed in the context of sleep research (evening dosing).

Is MK-677 FDA-approved?

No. MK-677 is not FDA-approved for any therapeutic use. Regulations vary by jurisdiction. All information presented here is for educational and research purposes only.

What is the half-life of MK-677?

The half-life of MK-677 is approximately 24 hours, which supports once-daily oral dosing in research protocols. Steady-state IGF-1 changes develop over several weeks.

Do I need to reconstitute MK-677?

No. MK-677 is orally active and is taken by mouth. The reconstitution tab on our calculator is provided only for researchers preparing oral solutions/suspensions from bulk material — it is not an injection protocol.

What are the side effects of MK-677?

Commonly reported effects include increased appetite, water retention, transient lethargy, and elevations in fasting glucose. Discuss any protocol with a licensed healthcare provider.